Article
Impact of gene polymorphisms in drug-metabolizing enzymes and transporters on trough concentrations of rivaroxaban in patients with atrial fibrillation.
Basic & clinical pharmacology & toxicology - 1 Feb 2021
Nakagawa Junichi, Kinjo Takahiko, Iizuka Mei, Ueno Kayo, Tomita Hirofumi, Niioka Takenori
Abstract excerpt
Rivaroxaban is excreted from the body via multiple pathways involving glomerular filtration, drug-metabolizing enzymes and transporters. In this study, we aimed to examine the impact of single nucleotide polymorphisms in P-glycoprotein, breast cancer resistance protein, cytochrome P450 (CYP) 3A5 and CYP2J2 on the pharmacokinetics of rivaroxaban. Eighty-six patients with non-valvular atrial fibrillation (NVAF)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
